PubRank

Sara Bar-Yehuda

Author PubWeight™ 18.70‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today 2011 1.44
2 The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. Clin Cancer Res 2004 1.36
3 Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol 2005 1.27
4 Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 2002 1.21
5 Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. J Rheumatol 2007 1.10
6 The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. Arthritis Res Ther 2006 1.09
7 A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 2002 1.07
8 An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene 2004 1.05
9 A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 2003 1.03
10 Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res 2003 1.02
11 Pharmacology and therapeutic applications of A3 receptor subtype. Curr Top Med Chem 2003 1.02
12 A3 adenosine receptor agonist potentiates natural killer cell activity. Int J Oncol 2003 0.96
13 Methotrexate enhances the anti-inflammatory effect of CF101 via up-regulation of the A3 adenosine receptor expression. Arthritis Res Ther 2006 0.95
14 CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. Oncologist 2013 0.86
15 IVIg to prevent tumor metastases (Review). Int J Oncol 2002 0.80
16 Targeting the A3 adenosine receptor for glaucoma treatment (review). Mol Med Rep 2013 0.79
17 Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine. Purinergic Signal 2011 0.79
18 A possible role for IVIg in the treatment of soft tissue sarcoma: a clinical case and an experimental model. Int J Oncol 2002 0.77